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Abstract
Vitamin B12 (cobalamin, Cbl) is a nutrient essential to human health. Due to its com-
plex structure and dual cofactor forms, Cbl undergoes a complicated series of absorp-
tive and processing steps before serving as cofactor for the enzymes methylmalonyl-
CoA mutase and methionine synthase. Methylmalonyl-CoA mutase is required for
the catabolism of certain (branched-chain) amino acids into an anaplerotic substrate
in the mitochondrion, and dysfunction of the enzyme itself or in production of its
cofactor adenosyl-Cbl result in an inability to successfully undergo protein catabolism
with concomitant mitochondrial energy disruption. Methionine synthase catalyzes the
methyl-Cbl dependent (re)methylation of homocysteine to methionine within the
methionine cycle; a reaction required to produce this essential amino acid and gener-
ate S-adenosylmethionine, the most important cellular methyl-donor. Disruption of
methionine synthase has wide-ranging implications for all methylation-dependent
reactions, including epigenetic modification, but also for the intracellular folate path-
way, since methionine synthase uses 5-methyltetrahydrofolate as a one-carbon donor.
Folate-bound one-carbon units are also required for deoxythymidine monophosphate
and de novo purine synthesis; therefore, the flow of single carbon units to each of
these pathways must be regulated based on cellular needs. This review provides an
overview on Cbl metabolism with a brief description of absorption and intracellular
metabolic pathways. It also provides a description of folate-mediated one-carbon
metabolism and its intersection with Cbl at the methionine cycle. Finally, a summary
of recent advances in understanding of how both pathways are regulated is presented.
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1 | INTRODUCTION
Functional metabolism of vitamin B12 and folate is critical to
human health. Vitamin B12 (cobalamin, Cbl) is not produced
in humans but is required for the function of two enzymes,
cytosolic methionine synthase (MS, EC 2.1.1.13) and mito-
chondrial methylmalonyl-CoA mutase (MUT, EC 5.4.99.2).1
MUT utilizes the adenosylated form of Cbl to catalyse the
conversion of L-methylmalonyl-CoA to succinyl-CoA. This
is an essential step in the catabolism of branched-chain amino
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acids, odd-chain fatty acids, and the side chain of cholesterol,
and contributes to anaplerotic replenishment of the tricarbox-
ylic acid cycle.2 By contrast, MS requires the methylated
form of Cbl and catalyzes the remethylation of homocysteine
to methionine using 5-methyltetrahydrofolate as methyl
donor. The importance of this reaction extends beyond the
production of methionine, an essential amino acid, because
methionine is further converted to S-adenosylmethionine
(AdoMet, often called SAM). The methyl group of AdoMet
can be donated to form a wide range of vitally important
methylated compounds, for example, creatine, epinephrine,
and sarcosine, as well as methylated DNA, RNA, and pro-
teins. The utilization of 5-methyltetrahydrofolate as methyl
donor by MS inexorably links Cbl metabolism with folate-
mediated one-carbon metabolism, which in addition to the
production of methionine and AdoMet, is required for de
novo purine synthesis, production of deoxythymidine mono-
phosphate (dTMP), and is an important cellular energy
source through reduction of NADP+ to NADPH. The impor-
tance of these pathways to human health is underlined by the
extent and severity of disease caused by their primary and
secondary dysfunction.
This review discusses Cbl and folate metabolism, with an
emphasis on the intracellular pathways involved in Cbl
cofactor synthesis, methionine remethylation, and one-
carbon metabolism. The biochemical functions and regula-
tion of individual proteins within these pathways are
discussed, along with the biochemical/cellular consequences
of their dysfunction. It is intended that this paper functions
as a stand-alone summary of current knowledge of cellular
Cbl and folate metabolism, while additionally may serve as
a primer for those readers interested in the clinical manifes-
tations of blocks in these pathways, presented in the adjoin-
ing paper “The clinical presentation of cobalamin-related
disorders: from acquired deficiencies to inborn errors of
absorption and intracellular pathways.”
2 | COBALAMIN METABOLISM—
STRUCTURE AND INTAKE
Once called “nature's most beautiful cofactor,”3 Cbl is at
least nature's most chemically complex coenzyme
(Figure 1). The focal point of Cbl is the central cobalt atom,
which can form between four and six bonds, and can exist in
the reduction states cob(III) (most oxidized), cob(II), or
cob(I)alamin (most reduced). There is a correlation between
the cobalt oxidation state and its preferred number of coordi-
nated elements, whereby cob(III)alamin often forms six
bonds, cob(II)alamin forms five bonds, and cob(I)alamin
forms four bonds. Of these, four cobalt bonds are always
occupied by the nitrogen atoms of the planar corrin ring sur-
rounding the cobalt. Cobalt may additionally bind a lower
axial ligand, the dimethylbenzimidazole (DMB) moiety
which attaches back to the corrin ring. When bound,
Cbl is considered “base-on,” when not “base-off.”
Finally, the cobalt atom may also or instead bind an
upper axial ligand (R-group), which may consist of
any number of compounds, but whose human cofactor
forms include the adenosyl- (adenosylcobalamin, AdoCbl)
or methyl- (methylcobalamin, MeCbl) moeities, while
glutathionyl- (glutathionylcobalamin, GNCbl) and
hyrdoxo- (hydroxocobalamin, OHCbl) are also physiologi-
cally important and cyano- (cyanocobalamin, CNCbl) is
common in pharmaceutical preparations.
Cbl approximates 1300 to 1500 Da in size, and its com-
plete synthesis requires more than 25 different steps, which
can occur aerobically or anaerobically4 at large energetic
cost. Complete Cbl synthesis is limited to selected Eubac-
teria and Archaea, whereas other Cbl-utilizing organisms
must modify Cbl acquired following uptake from other
sources.5 In humans, these sources are limited to animal
products, and therefore a certain proportion of the popula-
tion, with low intake of animal products, is moderately
vitamin B12 deficient,
6 even though dietary requirements are
only a few micrograms a day.1 Even processing of pre-
synthesized Cbl is complicated and metabolically costly;
currently, approximately 20 human genes are known to be
involved in absorption, selection, transport, modification,
and utilization of Cbl acquired from the diet.
FIGURE 1 Chemical structure of vitamin B12 (cobalamin). The
corrin ring and the dimethylbenizmidazole (DMB) moiety in the base-
on configuration are indicated. Grey dashed lines represent
nonessential bonds. R represents various upper axial ligands, including:
adenosyl, methyl, glutathionyl, hydroxo, and cyano
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Following ingestion of animal products containing vita-
min B12, rich sources of which include raw liver, kidney,
shellfish, meat, or dairy products (United States Department
of Agriculture (USDA) food composition database: https://
ndb.nal.usda.gov/ndb/nutrients/), Cbl is freed in the stomach
following proteolytic cleavage of the food stuffs. While still
within the stomach, freed Cbl is bound by the protein hapto-
corrin, which is thought to protect the vitamin against further
hydrolysis by the acidic environment.7,8 Haptocorrin itself is
degraded in the duodenum by proteases stemming from the
pancreas, following which intrinsic factor (IF) sequesters the
released Cbl.7,8 IF is synthesized and secreted by parietal
cells of the stomach, and its deficiency, either due to inborn
errors or an autoimmunity against the parietal cells, results
in classical pernicious anemia.9,10 At the terminal ileum, IF-
bound Cbl (IF-Cbl) is recognized by distinct cells (polarized
epithelial enterocytes), which express a complex receptor
composed of a heterodimer of amnionless and cubilin
(cubam) in the apical brush border, which mediates cellular
absorption of Cbl via endocytosis.11–13 Malabsorption at this
step occurs in the Imerslund-Gräsbeck syndrome, a rare dis-
order of Cbl deficiency14,15 caused by mutations of cubilin
(CUBN)16 or amnionless (AMN).17
Inside the cell, the IF-Cbl complex is released from
cubam, which recycles to the plasma membrane.12 IF is
degraded by the increasingly acidic environment during the
transition from endosome to lysosome. The exact details of
Cbl export across enterocytes remains to be clarified, but
likely requires many of the same steps as intracellular Cbl
processing in unpolarised cells (see next section). Export of
free Cbl from the cell into the bloodstream is mediated by at
least the basolateral multidrug resistance protein 1 (MRP1),18
although other methods/transporters may also be involved.19
In the blood, Cbl may be bound to either of two proteins—
haptocorrin or transcobalamin (TC).20 The far greater propor-
tion is bound by haptocorrin, but the affinity of haptorrin for
Cbl is lower than that of TC. Haptocorrin-bound Cbl is not
available to most cells. TC-bound Cbl, however, is readily
taken up by most cells of the body due to recognition by
CD320, the TC receptor.21 CD320 is expressed in virtually all
tissues,22 and CD320-mediated uptake promotes TC-Cbl
endocytosis. In the kidney, however, an important organ for
Cbl storage and recycling,23 uptake of TC-Cbl is instead
mediated by the protein megalin on the apical membrane of
proximal tubule cells.24,25
3 | INTRACELLULAR COBALAMIN
TRANSPORT AND MODIFICATION
Following uptake of TC-Cbl via receptor-mediated endocy-
tosis, intracellular synthesis of the cofactors AdoCbl and
MeCbl depends on intracellular transport and modification
of the incoming Cbls. The first step of this process is the
release of Cbl from TC, which occurs by the same process
as that for release of IF in enterocytes, that is, most likely by
progressive release from and degradation of the sequestering
protein in the acidic environment of the lysosome. Transport
of the now free Cbl out of the lysosome and into the cytosol
requires two integral membrane proteins, lipocalin-
1-interacting membrane receptor domain-containing
1 (LMBD1)26 and adenosine triphosphate (ATP)-binding
cassette subfamily D member 4 (ABCD4).27 Disturbed func-
tion of either of these proteins, which occurs in patients with
cblF and cblJ defects respectively, results in accumulation
of Cbl in the lysosome.
After export into the cytosol, Cbl is bound by the protein
methylmalonic aciduria cblC type with homocystinuria
(MMACHC), which then processes all incoming Cbls to a
common cob(II)alamin form. MMACHC has been shown
structurally28,29 to bind Cbl in a special base-off manner,
which facilitates biochemical removal of the upper axial
ligand either by reductive decyanation30 or dealkylation.31
Mutation of MMACHC, which occurs in patients with the
cblC defect,33 results in decreased availability of Cbl for
downstream enzymes, and the inability of cells to metabolize
and therefore utilize certain Cbl forms (eg, CNCbl). Follow-
ing reduction to cob(II)alamin, MMACHC-chaperoned Cbl
is then targeted to either MS or MUT by methylmalonic
aciduria cblD type with homocystinuria (MMADHC),34 a
protein which interacts with MMACHC only after
MMACHC has bound and processed Cbl.35 MMADHC con-
tains a mitochondrial leader sequence at its N-terminus, and
has been identified in both the cytosol and mitochondria.36
Mutation of MMADHC, as in the cblD defect,37 represents
the most unique genotype-phenotype relationship in intracel-
lular Cbl processing, whereby: (a) truncating mutations at
the N-terminus do not affect delivery of Cbl to MS, but
instead result in dysfunction of only MUT; (b) truncating
mutations in the middle and toward the C-terminus of the
protein result in disruption of cofactor synthesis/delivery to
both enzymes; and (c) certain missense mutations near the
C-terminus result in dysfunction of MS only.37–39
4 | THE MITOCHONDRIAL
COBALAMIN PATHWAY
The mechanism by which Cbl enters the mitochondrion
remains one of the great mysteries of Cbl metabolism. How-
ever, the recent discovery of mutation of wht-6 in Caenor-
habditis elegans causing disruption of the mitochondrial but
not cytosolic Cbl pathway in this organism is a tantalizing
clue that a human ortholog in the ATP-binding cassette
type G (ABCG) family of transporters may be the long
sought after mitochondrial importer.40 Once inside in the
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mitochondria (Figure 2), Cbl may be further chaperoned in
conjunction with MMADHC; however, data supporting this,
other than the observation that MMADHC is found within
the mitochondria, remain lacking. Mitochondrial Cbl is
sequestered by the protein methylmalonic aciduria cblB type
(MMAB), which catalyzes the ATP-dependent synthesis of
AdoCbl,41 the cofactor form of MUT. Patients with genetic
deficiency of MMAB, as in the cblB defect,42,44 suffer from
isolated methylmalonic aciduria (MMAuria) related to inad-
equate function of MUT. There is a mutational hotspot in
exon 7 of MMAB,32 which encodes the active site of the
protein.41 By analogy to bacterial homologs, AdoCbl trans-
fer from MMAB to MUT likely proceeds via direct associa-
tion between the two proteins.45 This transfer, however, is
gated by a third protein methylmalonic aciduria cblA type
(MMAA), which additionally appears to protect the AdoCbl
from oxidation during the MUT catalytic cycle in a guano-
sine triphosphate GTP dependent manner.46,47 Mutation of
MMAA in patients is described as the cblA defect,43 and
every patient mutation described to date either results in a
complete loss of MMAA protein or interferes with the inter-
action between MMAA and MUT.46
MUT itself catalyzes the rearrangement of L-methylma-
lonyl-CoA to succinyl-CoA in an AdoCbl dependent man-
ner. This pathway is an extension of the propionate catabolic
pathway, which is required for the breakdown of the
branched-chain amino acids valine, isoleucine, methionine
and threonine, odd-chain fatty acids and the side chain of
cholesterol, and whose product enters the tricarboxylic acid
cycle as an anapleurotic substrate. The mut-type MMAuria
due to mutation of MUT is the most common cause of iso-
lated MMAuria.1 The MUT protein consists of two domains,
an N-terminal substrate-binding and a C-terminal cofactor-
binding domain connected by a short linker, which exists in
a homodimeric state.48 Many of the patient mutations which
cause the generally more severe mut0 subtype of disease
occur within the substrate-binding domain, whereas muta-
tions within the cofactor-binding domain often result in the
usually later onset mut− disease subtype which at least
in vitro is Cbl responsive.49,50 Mutation of MCEE,51 the
enzyme directly upstream of MUT in the propionate cata-
bolic pathway, as well as in SUCLG152 or SUCLA253,54 the
genes encoding the heterodimeric enzyme succinate-CoA
ligase immediately downstream of MUT, also result in dis-
ease including MMAuria of milder degree.
5 | THE CYTOSOLIC COBALAMIN
PATHWAY AND THE METHIONINE
(REMETHYLATION) CYCLE
Successful delivery of Cbl to MS within the cytosol
depends on the concerted actions of MMACHC and
FIGURE 2 Intersection of the methylmalonyl-CoA catabolic pathway with adenosylcobalamin cofactor synthesis. Arrows depict enzymatic
reactions. Protein names are in bold. Cobalamin forms are in red. ABCD4, ATP-binding cassette subfamily D member 4; AdoCbl,
adenosylcobalamin; Cbl, cobalamin (no upper axial ligand attached); CoA, coenzyme A; Cyto, cytosol; LMBD1, lipocalin-1-interacting membrane
receptor domain-containing 1;MCEE, methylmalonyl-CoA epimerase; Mito, mitochondrion;MMAA, methylmalonic aciduria cblA type;MMAB,
methylmalonic aciduria cblB type;MMACHC, methylmalonic aciduria cblC type with homocystinuria;MMADHC, methylmalonic aciduria cblD
type with homocystinuria;MUT, methylmalonyl-CoA mutase; R-Cbl, cobalamin with upper axial ligand (eg, cyano-, hydroxo-) attached;
SUCLA2, succinate-CoA ligase ADP-forming beta subunit; SUCLG1, succinate-CoA ligase alpha subunit
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MMADHC, both of which have been shown to physically
interact with MS.55 Once Cbl has been successfully deliv-
ered to MS, it is bound and reduced in such a way that
cob(I)alamin is formed. This is the most reduced and reac-
tive Cbl form, which is primed to bind the methyl group
from the substrate 5-methyltetrahydrofolate and transfer it
to homocysteine, forming methionine and tetrahydrofolate
(THF) as products. Loss of MS function, owing to muta-
tion of the encoding gene MTR, is defined as the cblG
defect. This defect, or blocks in the synthesis of the cofac-
tor MeCbl, results in accumulation of homocysteine (hyper-
homocysteinemia, homocystinuria). A common dysfunction
of the MS enzymatic reaction is the inadvertent oxidation
of cob(I)alamin to cob(II)alamin, occurring approximately
every 1:200-1000 catalytic turnovers.56 This cofactor oxida-
tion renders MS enzymatically inactive, but it can be reacti-
vated by methionine synthase reductase (MSR) via
reductive methylation, a process which involves transfer of
an electron from MSR to MS, coupled with the transfer of
a methyl group from AdoMet.57 Dysfunction of MSR,
through mutation of its encoding gene MTRR, is defined as
the cblE defect.58
Intracellularly synthesized methionine, along with exoge-
nous sources, is available for incorporation into proteins or
further processing by the methionine cycle (Figure 3). The
next step in the methionine cycle is the formation of AdoMet
from methionine and adenosine triphosphate by methionine
adenosyltransferase (MAT). MAT consists of a liver-specific
isoenzyme (MAT1A) and a ubiquitously expressed isoen-
zyme (MAT2A) whose enzymatic activity is regulated by an
associated subunit (MAT2B). Dysfunction of MAT1A is
genetically linked with an inborn metabolic disorder of
hypermethioninemia,59,60 while MAT2A has been impli-
cated in predisposition to thoracic aortic aneurysms.61 Ado-
Met is the principal methyl donor in biological
transmethylation reactions, acting as substrate for a plethora
of methyltransferases (MTs). An estimated 1% of human
genes encode MTs.62 These enzymes are involved in numer-
ous cellular pathways and are responsible for methylation of
metabolites, DNA, RNA, and proteins,63 including his-
tones.64 Following transfer of the methyl-group, S-
adenosylhomocysteine (AdoHcy) is formed. This reaction
proceeds in the forward direction in vivo provided the prod-
ucts are removed. To this end, AdoHcy is processed to
homocysteine and adenosine by S-adenosylhomocysteine
hydrolase (AHCY). Mutation of AHCY is another cause of
hypermethioninemia.65 Successful formation of homocyste-
ine by AHCY completes the methionine cycle, creating a
homocysteine molecule that can be remethylated by MS, or
combined with serine to form cystathionine by cystathionine
beta-synthase as the first step in the transsulfuration pathway.
Alternatively, homocysteine may be remethylated by betaine
homocysteine methyltransferase, an enzyme that is most
strongly expressed in the liver and kidney66,67 and may play a
substantial role in production of methionine in those tissues.
A description of the genes/proteins involved in intracellu-
lar Cbl metabolism and the remethylation cycle is provided
in Table 1.
6 | FOLATE-MEDIATED ONE-
CARBON METABOLISM
The source of the MS substrate 5-methyltetrahydrofolate
(CH3-THF) is the one-carbon metabolic cycle, whose carrier
is folate. Folates encompass a set of molecules that contain
FIGURE 3 The remethylation pathway as depicted through the
folate cycle, methionine cycle and intracellular production of MeCbl.
Arrows depict enzymatic reactions. Protein names are in bold.
Cobalamin forms are in red. Single carbon groups originating from
formate and ending on methylated compounds are represented in blue.
ABCD4, ATP-binding cassette subfamily D member 4; Ado,
adenosine; AdoHcy, adenosylhomocysteine; AdoMet, S-
adenosylmethionine; AHCY, adenosylhomocysteinase; ATP,
adenosine triphosphate; Cbl, cobalamin (no upper axial ligand
attached); CH+-THF, 5,10-methenyltetrahydrofolate; CH2-THF,
5,10-methylenetetrahydrofolate; CH3-THF, 5-methyltetrahydrofolate;
CHO-THF, 10-formyltetrahydrofolate; CHOO−, formate; dTMP,
deoxythymidine monophosphate; Cyto, cytosol; LMBD1, lipocalin-
1-interacting membrane receptor domain-containing 1; Lyso,
lysosome;MATs, methionine adenosyltransferase(s); MeCbl,
methylcobalamin;MMACHC, methylmalonic aciduria cblC type with
homocystinuria;MMADHC, methylmalonic aciduria cblD type with
homocystinuria;MS, methionine synthase;MSR, methionine synthase
reductase;MTHFD1, methylenetetrahydrofolate dehydrogenase
1, cyclohydrolase and formyltetrahydrofolate synthetase 1;MTHFR,
methylenetetrahydrofolate reductase;MTs, methyltransferase(s); R-
Cbl, cobalamin with upper axial ligand (eg, cyano-, hydroxo-)
attached; SHMT, serine hydroxymethyltransferase
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(a) a pteridine ring that can be oxidized or reduced; (b) a
para-aminobenzoic acid linker that together with the pteri-
dine ring may bind one-carbon units; and (c) a variable-
length chain polyglutamate tail (Figure 4). Folic acid, an
oxidized folate form and a commonly used synthetic food
additive, is reduced at the double bond at nitrogen-8 to pro-
duce dihydrofolate (DHF), while further reduction of the
double bond at nitrogen-5 generates THF, the active coen-
zyme form. Both enzymatic steps are catalyzed by dihydro-
folate reductase (DHFR). Once reduced to THF, nitrogen-5
and/or nitrogen-10 may serve as acceptors of single carbon
units. These carbons may be transferred at varying oxidation
states, as determined by their source and the enzyme catalyz-
ing the reaction.
CH3-THF is the most common folate form in blood
and tissues.68 However, other folate forms in which the
bound carbon has a higher oxidation state also have vitally
important cellular roles. For example, 5,10-methylene-THF
(CH2-THF) is used by thymidylate synthase (TYMS) for
the production of dTMP from deoxyuridine monopho-
sphate (dUMP), an important step in DNA synthesis,
while 10-formyl-THF (CHO-THF) is required as a carbon
donor for two steps in de novo purine synthesis. The inter-
conversion between different folate forms occurs through
the folate-mediated one-carbon metabolic pathway, such
that the amount of a particular oxidation state of one-car-
bon-bound THF produced can be tailored according to cel-
lular needs. This pathway is mainly compartmentalized
between the cytosol and mitochondria, with smaller folate
amounts found in the nucleus69 (nuclear folate not dis-
cussed here, see for example, 70). An important determi-
nant of compartmentalization is the polyglutamate tail,
which appears to serve as a localization signal within the
cell. Monoglutamate but not polyglutamate forms is trans-
ported across the intestine by the proton-coupled folate
transporter,71 the plasma membrane by the reduced folate
carrier72 and across the mitochondrial membrane by the
mitochondrial folate transporter,1,73 whereby polyglutamate
forms are trapped intracellularly within the compartment
the glutamate tail was added. This means circulating
folates are also in the monoglutamate form, which may
additionally be processed by the folate receptor that has
particular significance at the choroid plexus.74 Another
contributor to compartmentalization is that folates with
one-carbon units bound (eg, CHO-THF, CH3-THF), are
FIGURE 4 Structure of folic acid. Nitrogen-5, −8 and − 10, are
acceptors of hydrogen and/or carbon groups. Glutamate may exist as
n = 1 (monoglutamate) or as a chain of n = 2-10 (polyglutamate)
TABLE 1 Description of genes/proteins involved in intracellular Cbl metabolism and remethylation
Protein
name Gene name
Complementation
group
Protein cellular
location Cellular/enzymatic function
LMBD1 LMBRD1 cblF Lysosome Transport of Cbl across lysosomal membrane?
ABCD4 ABCD4 cblJ Lysosome Transport of Cbl across lysosomal membrane?
MMACHC MMACHC cblC Cytosol Cbl chaperone/enzyme
MMADHC MMADHC cblD Cytosol/Mito Targeting MMACHC-Cbl complex to MS/MUT?
MMAA MMAA cblA Mito Protection of MUT
MMAB MMAB cblB Mito ATP + cob(I)alamin ! AdoCbl + PPPi
MUT MUT mut Mito L-methylmalonyl-CoA ! succinyl-CoA
MS MTR cblG Cytosol Homocysteine + CH3-THF ! methionine + THF
MSR MTRR cblE Cytosol Cob(II)alamin + AdoMet! methylcobalamin + AdoHcy
MTHFD1 MTHFD1 Cytosol/nucleus CHOO− + THF ! CHO-THF ! CH+-THF ! CH2-THF
MTHFR MTHFR Cytosol CH2-THF ! CH3-THF
SHMT SHMT1 Cytosol/nucleus CH2-THF + glycine! THF + serine
MATI/III
or II
MAT1A/MAT2A Cytosol ATP + methionine ! AdoMet + PPPi
MT Various Various Substrate + AdoMet! methyl-substrate + AdoHcy
AHCY AHCY Cytosol AdoHcy! adenosine + homocysteine
Mutation of genes above the dashed line results in inherited disorders of cobalamin metabolism, below results in disorders of remethylation/methionine cycle.
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not known to cross the mitochondrial membrane.75 Finally,
only a limited number of nonfolate metabolic intermediates
within the one-carbon metabolic pathway are able to cross
the mitochondrial membrane. Together, these lead to sepa-
ration of the mitochondrial and cytosolic one-carbon meta-
bolic pathways, which are connected only via specific
metabolites. These separated pathways remain functional,
however, because a complete set of enzymes exist in both
compartments. It is not clear why a parallel set of
enzymes in the cytosol/mitochondria are required, espe-
cially when the vast majority of one-carbon need is in the
cytosol. However, an important clue may come from the
finding that mitochondrial one-carbon oxidation accounts
for approximately 50% of the NADPH produced in the
cell,76 a massive reducing and energy source. From this
has stemmed the hypothesis that one-carbon oxidation is
localized to the mitochondria in order to uncouple it from
glycolysis, which might be blocked by the depleted NAD+
levels that would arise should one-carbon oxidation take
place in the cytosol.73
In humans, the major source of one-carbon units is serine,
which in the presence of THF is reversibly metabolised to gly-
cine and CH2-THF by the enzyme serine hydroxymethyltrans-
ferase (SHMT). At least two different isozymes of SHMT
(cytosolic SHMT1 and mitochondrial SHMT2) exist, encoded
by separate genes (SHMT1 and SHMT2, respectively). Studies
using deuterated serine have demonstrated that the majority of
one-carbon units transferred to methionine in healthy volun-
teers77 and in cell culture78 originate from the mitochondria
(ie, starting from SHMT2), and this has been found to be the
case in most cancer cell types as well.79 Therefore, the folate
cycle may be thought to begin with demethylation of serine
by mitochondrial SHMT2 in the presence of free THF, to
form glycine and CH2-THF (Figure 5). The cycle continues
with the two-step oxidation of CH2-THF to methenyl-THF
(CH+-THF) and then CHO-THF by bifunctional methylenete-
trahydrofolate dehydrogenase 2 (MTHFD2) or MTHFD2 like
(MTHFD2L), isoenzymes with different expression pat-
terns.80,81 The final mitochondrial step is the formation of for-
mate and free THF by methylenetetrahydrofolate
dehydrogenase 1 like (MTHFD1L). Formate is an important
intermediate that is able to cross the mitochondrial membrane,
and whose availability in the cytosol is an important determi-
nant of the direction in which the cytosolic pathway pro-
ceeds.82 Within the cytosolic pathway,
methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) cata-
lyzes the incorporation of formate back into free THF to form
CHO-THF, a required substrate for de novo purine synthesis,
donating two carbon groups to the purine ring through the
purinosome enzymes GART and ATIC, respectively
(Figures 3 and 5). CHO-THF may alternatively be succes-
sively reduced to CH2-THF by the second and third functions
of the trifunctional enzyme MTHFD1. CH2-THF has alterna-
tive fates depending on the needs of the cell: the remethylation
of glycine to serine by SHMT1 to complete the folate cycle;
the production of dTMP from dUMP for DNA synthesis by
TYMS; or final reduction to CH3-THF by methylenetetrahy-
drofolate reductase (MTHFR), providing the substrate for MS
and the methionine cycle. This last option commits THF for
use by MS, as the MTHFR catalyzed reduction is physiologi-
cally irreversible and MS is the only enzyme that utilizes
CH3-THF. One important consequence of this is that in the
presence of MS deficiency, cellular folates may become
trapped in the CH3-THF form. This results in an inability to
FIGURE 5 Simplified folate-mediated one-carbon metabolism pathway in the cytosol and mitochondria. Arrows represent enzymatic
reactions or transmembrane transport. Broken arrows represent multiple enzymatic steps. Numbers indicate the enzyme(s) responsible for the
enzymatic reaction as follows (provided where possible as the human gene name): 1) SHMT2, 2) MTHFD2/MTHFD2L, 3) MTHFD2/MTHFD2L,
4) MTHFD1L, 5) MTHFD1 (synthetase), 6) MTHFD1 (cyclohydrolase), 7) MTHFD1 (dehydrogenase), 8) SHMT1, 9) GART and ATIC (in the de
novo purine synthesis pathway), 10) MTHFR, 11) TYMS, 12) DHFR, 13) MTR, 14) MAT1A or MAT2A, 15) AdoMet-dependent
methyltransferase, 16) AHCY, 17) CBS, 18) CTH
FROESE ET AL. 679
produce purines and dTMP, which is especially debilitating
for quickly dividing cells (eg, blood cells in the bone marrow)
and is the presumed cause of megaloblastic anaemia in Cbl
deficiency.
The relative importance of each endpoint in the cytosolic
pathway (purine synthesis, dTMP synthesis or methioni-
ne/AdoMet synthesis) has been investigated by supplying
labeled serine or formate to various cell types, followed by
determination of the relative incorporation of label to each
of these final compounds. In quickly proliferating cells,
including cultured cancer cells, stem cells, hematopoietic
cells, and during development, the majority of labeled car-
bons are incorporated into purines and dTMP (reviewed in:
73,83), reflecting the predominant requirement of these cell
types for DNA synthesis. In these situations, cells are exqui-
sitely sensitive to folate depletion, manifesting in the effi-
cacy of the folate analogs methotrexate and pemetrexed for
cancer treatment,84 in neural tube defects arising from folate
insufficiency85 or mouse knockouts of mitochondrial folate
processing enzymes,86 and in the macrocytic/megaloblastic
anaemia presented in patients with insufficient folate uptake
or blockages in folate processing.1 In slowly proliferating
fibroblasts in culture, Stover and colleagues87 found that
compared to control cells, the incorporation of formate into
methionine of MTHFD1 deficient fibroblasts was decreased
by 90% and into dTMP by 50%, but purine incorporation
was unchanged. This again is consistent with sacrifice of the
methionine cycle in favour of protecting nucleotide synthesis
in this cell type. In nonproliferating cells, however, cellular
requirements are different. In the adult liver and kidney, two
major reservoirs of anabolic one-carbon reactions, a signifi-
cant proportion of one-carbon groups likely flow through
the methionine cycle. In these tissues, methionine cycle pro-
duced AdoMet is required for the synthesis of creatine and
phosphotidylcholine, creation of which account for up to
80% of all methylation reactions in the body.88
7 | ALLOSTERIC, GENETIC, AND
EPIGENETIC REGULATION
Due to the vital nature and interconnection of the intracellu-
lar Cbl, methionine synthesis and one-carbon metabolic
pathways, these processes undergo regulation to ensure the
best use of the often limited substrates or cofactors available.
While some of these regulation mechanisms have been
known for some time, for example, allosteric enzyme modu-
lation by AdoMet and AdoHcy, exciting emerging concepts
regarding regulation at the gene, mRNA and enzyme level
have recently been identified.
In terms of intracellular Cbl cofactor synthesis, there is
now compelling evidence for the regulation of MMACHC
expression. The first piece of evidence was provided in
patients who had loss of MMACHC activity and expression
despite harbouring no identifiable mutations in the
MMACHC gene. These patients were eventually found to
harbour mutations in the kelch domain of the transcriptional
coregulator host cell factor C1 (HCFC1),89–91 a molecular
scaffold whose function is critical for cell proliferation and
cell-cycle progression.92,93 Control of the cell cycle by
HCFC1 has been shown to require formation of a complex
with the transcription factors THAP domain-containing pro-
tein 11 (THAP11) and zinc finger protein 143 (ZNF143).94
Indeed, mutation of both THAP1195 and ZNF14396 has been
shown to result in loss of MMACHC expression and clinical
Cbl deficiency, thus demonstrating that this complex is also
involved in MMACHC expression. This provides a link
between Cbl cofactor synthesis and cell growth and prolifera-
tion, which connects the methionine and one-carbon cycles as
well (see below). Interestingly, putative HCFC1 binding sites
were also identified in the promoters of MTR and ABCD4;
however, analysis of RNA and protein expression of these
genes in fibroblasts showed no difference between HCFC1
patients and controls.91 In an alternative mechanism, loss of
MMACHC expression has been described to be due to muta-
tion of its neighbouring antisense oriented gene PRDX1, which
causes hypermethylation of the promoter and first exon of
MMACHC and thereby causes MMACHC silencing.97 Thus
far, no other regulatory mechanisms have been described for
proteins proximal to MMACHC in the intracellular Cbl path-
way (ie, LMBD1 and ABCD4) or in the mitochondrial path-
way (ie, MMAA, MMAB, MMADHC, and MUT).
MS sits at the conjunction of the Cbl cofactor synthesis
pathway and the methionine cycle and therefore may repre-
sent a prime location for the regulation of both cycles simul-
taneously. A potential site of regulation was found on a
70-bp stretch of the 50-untranslated region MTR mRNA.
This site was suggested to be modulated by Cbl at an inter-
nal ribosome entry site (IRES) in conjunction with an uni-
dentified protein.98,99 Unfortunately, these tantalizing initial
findings have not been followed up, and evidence for the
existence of the IRES is disputed.100 Nevertheless, clues to
the presence of regulated expression of MTR exist. For
example, homocysteine has been found to increase mRNA
levels in Caco-2 cells,101 a link between MTR expression
and the cell cycle has been found, whereby the MTR mRNA
level is elevated during the S phase of synchronized U2OS
cells,102 and MS activity is found to be lowest during G0
and G1 in human lymphocytes.
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Beyond MS, but within the methionine (re)methylation
cycle, regulation of pathway activity at the enzymatic level
by the metabolites AdoMet and AdoHcy is historically well
known. Increased concentrations of AdoMet result in allo-
steric inhibition of MTHFR104 and MAT2A105,106 as well as
concomitant activation of cystathionine β-synthase,107
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ensuring no new AdoMet is produced while excess homo-
cysteine is released from the cycle. By contrast, increased
local concentrations of AdoHcy enable dis-inhibition of
MTHFR108 along with inhibition of AdoMet-dependent
MTs.109,110
Recently, a new intracellular sensor of AdoMet has been
described. This new sensor, SAMTOR, has a relatively low
dissociation constant for AdoMet of ~7 μM and interacts
with the Gap Activity TOward Rags 1 (GATOR1)-complex
associated with mammalian Target Of Rapamycin Complex
1 (mTORC1), the major regulator of cell growth and metab-
olism based on environmental cues,111 when intracellular
AdoMet is depleted. Since methionine and AdoMet produc-
tion are closely related, SAMTOR has also been suggested
to serve as the mTORC1 linked sensor of methionine starva-
tion. A further link between the methionine cycle and
mTORC1 has been identified in mice with knockout of
nitrogen permease regulator-like 2 (NPRL2), a protein
within the GATOR1 complex.112 NPRL2 knockout mice
exhibit low methionine and high CH3-THF levels character-
istic of MS deficiency, which in this case is due to the inabil-
ity to generate the low lysosomal pH required for release of
free Cbl from transcobalamin. This dysfunction ultimately
stems from lysosomal gene expression inhibition by the con-
stitutively active mTORC1, and exhibits a mechanism by
which mTORC1 may act back on the methionine cycle.
Finally, Manning and colleagues113 found that mTORC1
stimulates de novo purine synthesis in mouse embryonic
fibroblasts by inducing MTHFD2 transcription via activating
transcription factor 4 (ATF4), a transcription factor involved
in control of the cell cycle.
This latter finding illustrates the connection between
these pathways and the cell cycle, which has been found for
other proteins as well. A recent review by Stover and col-
leagues70 points out that MTHFD1 is predominantly
expressed in the G1/S and G2 phases of the cell cycle in
human fibroblasts,114 although the mechanism by which this
regulation takes place is unclear. SHMT1 protein levels, by
contrast, are elevated during the S phase of HeLa cells, but
without changes in mRNA levels.115,116 Meanwhile, we
found that phosphorylation of MTHFR leads to an increased
sensitivity to AdoMet inhibition,117 and the kinase responsi-
ble for this phosphorylation has been suggested to be the
cyclin dependent kinase 1 (CDK1) in association with cyclin
B1.118 Together, these data provide a link between the cell-
cycle state and regulation of proteins involved in methionine
cycle or the one-carbon metabolic pathway.
A further level of complexity of regulation exists in that
these pathways may in turn regulate the expression of other
genes and pathways in the cell. Studies performed mainly in
cancer cells have indicated that altered methionine metabo-
lism has an effect on histone methylation via altered function
of histone MTs.119,120 Histone methylation drives gene
expression up or down, depending on the modification
placement. Since various histone MTs have differing affini-
ties for AdoMet, decreased or fluctuating intracellular con-
centrations may have a larger impact on some histone
modifications than others.64 In relation to just one type of
histone methylation, transcriptionally activating H3K4me3,
Locasale and colleagues121 found that modulating dietary
methionine intake was sufficient to alter levels of histone
methylation, with rapid changes in H3K4me3 levels and
altered gene transcription following changes in methionine
availability. Therefore, alterations in the methionine cycle,
for example, due to genetic blocks in Cbl or folate pathway
proteins, do not just result in hyper- or hypo-methylation,
but altered methylation patterns. This is consistent with find-
ings from an epigenome-wide association study performed
in 90 mouse inbred strains, which found that genetic varia-
tion in Mtrr (encoding MSR) affected methylation of almost
500 loci throughout the genome.122 These methylation
changes may have long-term effects, as transgenerational
epigenetic inheritance ultimately coming from the maternal
grandparents was found to result in intrauterine growth
restriction, developmental delay, and congenital malforma-
tions in hypomorphic Mtrr mice.123
In sum, the Cbl, methionine, and folate biochemical path-
ways are interlinked with other crucial pathways in the cell,
with each exerting regulatory influence on the other.
8 | CONCLUSIONS/OUTLOOK
Within the cell, metabolism of Cbl and folate is interrelated.
These pathways are joined metabolically at the methionine
cycle, but are connected by regulation through other cellular
metabolic and regulatory pathways at many points. Although
shared function and regulation through particular metabolites
have been known for some time, only now are we beginning
to realise the extent to which these pathways are interdepen-
dent. This continued understanding of the effect alterations
in single steps, either via regulation or through genetic
blocks, has on all aspects of these pathways may finally
bring us to a state where we can better comprehend, and per-
haps predict, what will happen during therapeutic modula-
tion or disease. This will be key to better modulating these
pathways in health and disease.
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